A delay integro-differential equation model fitted to pharmacokinetic and RNA-seq data indicates that a single medium-to-high dose of pembrolizumab may suffice for effective neoadjuvant eradication of locally advanced MSI-H/dMMR colorectal tumors.
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
q-bio.CB 1years
2024 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations
A delay integro-differential equation model fitted to pharmacokinetic and RNA-seq data indicates that a single medium-to-high dose of pembrolizumab may suffice for effective neoadjuvant eradication of locally advanced MSI-H/dMMR colorectal tumors.